Peptide Technology
At the heart of Ferring’s work with peptide technology are amino-acids1, the building blocks of life, developed and optimised by nature over billions of years to build proteins, receptors and peptide hormones. Ferring’s peptide technology and know-how combines naturally-occurring, DNA-coded, amino acids with large collections of proprietary synthetic amino acids to “improve on nature” by overcoming the typical limitations of endogenous2 peptides and hormones, primarily pleiotropic3 and short-lived actions.
The resulting “drug-like” molecules retain the key advantages of naturally-occurring peptides and hormones (high potency, high efficacy and high safety), while offering improved pharmacodynamics4 (receptor and function selectivity), pharmacokinetics5 (enzymatic stability6, clearance, half-life and duration of action) and pharmaceutical properties (solubility and stability).
History of peptides at Ferring
Ferring’s founder Dr Frederik Paulsen chose to develop Ferring’s first medicines using peptide hormones. Initially, Ferring produced peptides through extracting them from animal organs and then modifying them using natural hormones7 and/or ligands8.
Ferring developed production techniques that allowed the chemical synthesis9 of peptides, thus removing the need to extract peptides from animal organs. In the 1960s Ferring became one of the first pharmaceutical companies in the world to synthesise oxytocin10 and vasopressin11 thus establishing Ferring as a peptide company.
Ferring then collaborated with various academic and research institutes to adapt vasopressin11 and oxytocin10 in order to improve their pharmacological12 properties. This work led to the development of medicines to treat diabetes insipidus13, enuresis14, bleeding disorders as well as treatments for the prevention of post caesarean haemorrhage and for the management of premature labour. 8) ligands - A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme.